Arrowhead Pharmaceuticals
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challeng...
Latest News
4 days ago · seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript
4 days ago · marketbeat.com
Arrowhead Pharmaceuticals Q4 Earnings Call HighlightsArrowhead Pharmaceuticals NASDAQ: ARWR is preparing for a potential U.S. launch of its drug REDEMPLO in a larger patient population in the second quarter of 2027, as the company works to turn growing prescription demand for the medicine into paid treatments.
7 days ago · businesswire.com
Arrowhead Pharmaceuticals to Participate in Upcoming Investor ConferencesPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026 Jefferies Global Healthcare Conference in London – November 16-19, 2026Type: Fireside Chat PresentationDate/Time: November 18, 2026, 11:00 am GMTCiti's 2026 Global Healthcare Conference – November 30 - December 3, 2026Type: Fireside Chat PresentationDate/Time: December 2, 2026, 2:20 pm ESTPiper Sandler 38th Annual Hea.
9 days ago · businesswire.com
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis RatesPASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. The presentations included multiple studies of plozasiran in patients with familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG), and interim results from a Phase 1/2a study of investigational ARO-DIMER-PA.
13 days ago · businesswire.com
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending MaturityPASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases financial and operational flexibility. The transaction retires Arrowhead's existing $400 million Sixth Street facility at a $68 million discount to the contractual minimum repayment amount and establishes a new $400 million Si.
15 days ago · businesswire.com
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week's American Heart Association Scientific Sessions in Chicago. AHA 2026 Oral Presentations Date & Time: Saturday, November 7, 3:15 – 4:30 pm CT Session Title: FS.05: Featured Science Session on Novel Lipid Lowering Therapies Location: Learning Studio 2‚ Science and Technology Hall‚ South Hall Title: First-in-Human Trial of a Dual Functional RNAi Mo.
1 month ago · seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline TranscriptArrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
2 months ago · seekingalpha.com
Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million VoucherArrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia (sHTG) with plozasiran, leveraging a faster launch via a $215M priority review voucher. ARWR's SHASTA-3 and SHASTA-4 Phase III data show plozasiran achieves 79–81% median triglyceride reductions and favorable safety, with quarterly dosing and no liver fat or thrombocytopenia signals. Current financials reflect partner-driven revenue and a strategic buildout for sHTG; liquidity of ~$1.35B post-voucher supports operations into early 2028, but further funding may be needed as SG&A rises.
2 months ago · marketbeat.com
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline ExpandsArrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disorders.
2 months ago · seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptArrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ARWR